Skip to main content
. 2020 Jun 24;41(36):3421–3432. doi: 10.1093/eurheartj/ehaa419

Table 4.

Changes in blood pressure after 12 months of dapagliflozin treatment

Variable change Intention-to-treat analysis
Per-protocol analysis
Dapagliflozin Placebo Differencea P-value Dapagliflozin Placebo Differencea P-value
(n = 32) (n = 34) (95% CI) (n = 29) (n = 33) (95% CI)
24 h SBPb −2.78 ± 5.94 0.85 ± 5.40 (n = 33) −3.63 (−6.44 to −0.82) 0.012 −3.07 ± 6.18 0.88 ± 5.48 (n = 32) −3.94 (−6.93 to −0.96) 0.011
24 h DBPb −0.94 ± 3.98 0.06 ± 4.87 (n = 33) −0.1 (−3.2 to 1.21) 0.370 −1.03 ± 4.18 0.06 ± 4.94 (n = 32) −1.1 (−3.46 to 1.260 0.356
Heart rateb–d −2.00 ± 5.75 1.00 ± 8.50 (n = 33) −2.1 (−5.64 to 1.43) 0.184 −2.0 ± 7.5 1.0 ± 8.80 (n = 32) −2.27 (−6.05 to 1.51) 0.183
Daytime SBPb −2.47 ± 6.56 0.55 ± 6.45 (n = 33) −3.01 (−6.24 to 0.21) 0.066 −2.72 ± 6.85 0.56 ± 6.55 (n = 32) −3.29 (−6.72 to 0.15) 0.060
Daytime DBPb −1.03 ± 5.18 0.24 ± 5.80 (n = 33) −1.27 (−4.00 to 1.46) 0.355 −1.14 ± 5.44 0.25 ± 5.90 (n = 32) −1.39 (−4.30 to 1.53) 0.345
Nocturnal SBPe −3.47 ± 7.54 0.91 ± 6.70 (n = 32) −4.38 (−7.94 to −0.81) 0.017 −3.83 ± 7.84 0.94 ± 6.81 (n = 31) −4.76 (−8.55 to −0.98) 0.015
Nocturnal DBPe −2.25 ± 5.90 0.16 ± 4.14 (n = 32) −2.41 (−4.95 to 0.14) 0.063 −2.48 ± 6.16 0.16 ± 4.20 (n = 31) −2.64 (−5.35 to 0.06) 0.059
Office SBP −5.28 ± 8.63 −1.79 ± 7.26 −3.49 (−7.40 to 0.43) 0.080 −5.83 ± 8.89 −1.85 ± 7.37 −3.98 (−8.11 to 0.15) 0.059
Office DBP −2.97 ± 5.62 −2.24 ± 7.48 −0.73 (−4.00 to 2.54) 0.656 −3.27 ± 5.82 −2.30 ± 7.58 −0.97 (−4.39 to 2.44) 0.577

P-values in bold indicate <0.05.

DBP, diastolic blood pressure; SBP, systolic blood pressure.

a

Absolute mean Difference between groups. All other values expressed in mean ± SD unless stated.

b

One participant unable to tolerate any ambulatory blood pressure monitoring.

c

Median ± IQR.

d

Twenty-four hour heart rate recorded during ambulatory blood pressure monitoring.

eOne further participant unable to tolerate overnight blood pressure monitoring.